November 18, 2024New England Journal of Medicine71 citations
View Full PaperPhase 1 Study of AAV9.LAMP2B Gene Therapy in Danon Disease
Key Result
A single infusion of RP-A501 gene therapy in male patients with Danon disease appeared safe and was associated with cardiac LAMP2 expression and clinical improvement over 24 to 54 months.
Structured PICO
Does RP-A501 gene therapy improve safety, cardiac LAMP2 expression, and clinical outcomes in male patients with Danon disease?
P
Population
7 male patients with Danon disease, aged 11 years and older, followed for 24 to 54 months after receiving RP-A501 gene therapy.
I
Intervention
Single infusion of RP-A501 (AAV9.LAMP2B gene therapy) along with a transient immunomodulatory regimen of prednisone, tacrolimus or sirolimus, and rituximab
O
Outcome
Safety and toxic effects of RP-A501, myocardial LAMP2 transduction and protein expression, stabilization of or reduction in heart-failure symptoms, and stabilization of or improvement in cardiac structure and functionsafety
A single infusion of RP-A501 gene therapy appears safe and is associated with cardiac LAMP2 expression and clinical stabilization in male patients with Danon disease over 2 to 4.5 years.
Abstract
BACKGROUND: ), which encodes the LAMP2 protein. In male patients, the predominant phenotype is progressive cardiac hypertrophy, cardiac dysfunction, and early death. There are no directed therapies for the disease. METHODS: , which encodes an isoform of LAMP2. The primary outcomes were the safety and toxic effects of RP-A501, myocardial LAMP2 transduction and protein expression, stabilization of or reduction in heart-failure symptoms, and stabilization of or improvement in cardiac structure and function. Key secondary outcomes were sustained reduction in or stabilization of symptoms, immunologic response to RP-A501, end-stage heart failure, and overall survival. Exploratory outcomes included improvement in serologic markers of cardiac disease, patient-reported outcomes, and quality-of-life assessments. RESULTS: RP-A501 infusion was administered to seven male patients with Danon disease: five who were 15 years of age or older and two who were between 11 and 14 years of age. All the patients received a transient immunomodulatory regimen of prednisone, tacrolimus or sirolimus, and rituximab. Phase 1 data over 24 to 54 months, including interim data from a long-term follow-up study, are reported here. One patient had complement-mediated thrombotic microangiopathy (grade 4) with thrombocytopenia and acute kidney injury. Three patients had glucocorticoid-related exacerbation (grade 3) of Danon disease-related skeletal myopathy. One patient with left ventricular systolic dysfunction at baseline had progressive heart failure and underwent transplantation 5 months after infusion. In the six patients with normal left ventricular ejection fraction at baseline, we observed cardiac LAMP2 protein expression and a reduction from baseline in or stabilization of the left ventricular mass index, preservation of left ventricular ejection fraction, and reduction in or stabilization of the levels of cardiac troponin I and N-terminal pro-B-type natriuretic peptide. At 24 to 54 months, all the patients were alive, with complete resolution of side effects. CONCLUSIONS: A single infusion of RP-A501 appeared to be safe and was associated with cardiac LAMP2 expression and evidence of clinical improvement over a period of 24 to 54 months. (Funded by Rocket Pharmaceuticals; ClinicalTrials.gov number, NCT03882437.).